Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
- Conditions
- Cardio-pulmonary BypassCoronary Artery Bypass Graft
- Registration Number
- NCT00048308
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Brief Summary
During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (180)
Baptist Medical Center Cardiology
🇺🇸Birmingham, Alabama, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
IMC-Diagnostic and Medical Clinic
🇺🇸Mobile, Alabama, United States
Desert Samaritan - Lutheran Heart
🇺🇸Mesa, Arizona, United States
Good Samaritan Regional Medical Center
🇺🇸Phoenix, Arizona, United States
Saguaro Clinical Research
🇺🇸Tucson, Arizona, United States
Southern Arizona VAMC
🇺🇸Tucson, Arizona, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
Sparks Regional Medical Center
🇺🇸Fort Smith, Arkansas, United States
University of Arkansas
🇺🇸Little Rock, Arkansas, United States
Scroll for more (170 remaining)Baptist Medical Center Cardiology🇺🇸Birmingham, Alabama, United States